Tocilizumab (Actemra) and siltuximab (Sylvant) are the two FDA- approved anti-IL6 drugs with tocilizumab approved for the treatment of rheumatoid arthritis(RA) [158], it has been investigated in the context of cancer for its potent anti-inflammatory effects like large-cell lung carcinoma [159] and siltuximab approved for the treatment of multicentric Castleman’s disease [160]. The gene discussed is IL6; the disease is cancer.